Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Motwani, M.
Right arrow Articles by Schwartz, G. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Motwani, M.
Right arrow Articles by Schwartz, G. K.
Clinical Cancer Research Vol. 7, 4209-4219, December 2001
© 2001 American Association for Cancer Research

Experimental Therapeutics, Preclinical Pharmacology

Augmentation of Apoptosis and Tumor Regression by Flavopiridol in the Presence of CPT-11 in Hct116 Colon Cancer Monolayers and Xenografts1

Monica Motwani, Christoph Jung, Francis M. Sirotnak, Yuhong She, Manish A. Shah, Mithat Gonen and Gary K. Schwartz2

Gastrointestinal Oncology Research Laboratory, Division of Solid Tumor Oncology, Department of Medicine [M. M., C. J., M. A. S., G. K. S.], Program of Molecular Pharmacology and Experimental Therapeutics [F. M. S., Y. S.], and Department of Epidemiology and Biostatistics [M. G.], Memorial Sloan Kettering Cancer Center, New York, New York 10021

CPT-11, a DNA topoisomerase I inhibitor, has demonstrated clinical activity in colorectal cancer. Flavopiridol, a cyclin-dependent kinase inhibitor, is rapidly emerging as a chemotherapy modulator. To enhance the therapeutic index of CPT-11 in colon cancer, we studied the combination of these two drugs in relatively resistant human colon cancer cells, Hct116. Exposure of parental Hct116 cells to clinically achievable concentrations of SN-38 (the active metabolite of CPT-11) induces p21 and a G2 arrest. However, these conditions fail to induce apoptosis. In contrast, Hct116 cells that are p21 deficient (p21-/- Hct116) readily undergo apoptosis after treatment with SN-38. In this study we show that the parental Hct116 cells can be sensitized to undergo apoptosis by the addition of flavopiridol after SN-38 treatment. The induction of apoptosis was greatest with sequential therapy consisting of SN-38 followed by flavopiridol. Clonogenic assays also showed greatest inhibition with this sequence. Sequential treatment with SN-38 followed by flavopiridol was associated with higher activation of caspase-3 and greater cleavage of both p21 and XIAP, an inhibitor of apoptosis, compared with other treatment schedules. CPT-11 induced some tumor regressions but no complete responses in the p21-intact Hct116 xenografts. CPT-11 with flavopiridol more than doubled tumor regression, compared with CPT-11 alone, and produced a 30% complete response rate. Our studies indicate that CPT-11 induces cell cycle arrest rather than cell death and that flavopiridol, by activating the caspase cascade, cleaves the inhibitors of apoptosis and sensitizes the cells to undergo cell death. Thus, flavopiridol combined with CPT-11 may provide a completely new therapeutic approach in the treatment of colon cancer.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
G. Ambrosini, S. L. Seelman, L.-X. Qin, and G. K. Schwartz
The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates the Effects of Topoisomerase I Poisons by Suppressing Rad51 Expression in a p53-Dependent Manner
Cancer Res., April 1, 2008; 68(7): 2312 - 2320.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Perrone, S. Suardi, E. Pastore, P. Casieri, M. Orsenigo, S. Caramuta, G. Dagrada, M. Losa, L. Licitra, P. Bossi, et al.
Molecular and Cytogenetic Subgroups of Oropharyngeal Squamous Cell Carcinoma.
Clin. Cancer Res., November 15, 2006; 12(22): 6643 - 6651.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
C. P. Fanton, M. W. Rowe, E. J. Moler, M. Ison-Dugenny, S. K. De Long, K. Rendahl, Y. Shao, T. Slabiak, T. G. Gesner, and M. L. MacKichan
Development of a screening assay for surrogate markers of chk1 inhibitor-induced cell cycle release.
J Biomol Screen, October 1, 2006; 11(7): 792 - 806.
[Abstract] [PDF]

Home page
 JCOHome page
G. I. Shapiro
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
J. Clin. Oncol., April 10, 2006; 24(11): 1770 - 1783.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. K. Schwartz and M. A. Shah
Targeting the Cell Cycle: A New Approach to Cancer Therapy
J. Clin. Oncol., December 20, 2005; 23(36): 9408 - 9421.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
X. Lu, J. i. Jung, H. J. Cho, D. Y. Lim, H. S. Lee, H. S. Chun, D. Y. Kwon, and J. H. Park
Fisetin Inhibits the Activities of Cyclin-Dependent Kinases Leading to Cell Cycle Arrest in HT-29 Human Colon Cancer Cells
J. Nutr., December 1, 2005; 135(12): 2884 - 2890.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. K. Schwartz
Development of Cell Cycle Active Drugs for the Treatment of Gastrointestinal Cancers: A New Approach to Cancer Therapy
J. Clin. Oncol., July 10, 2005; 23(20): 4499 - 4508.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. Shah, J. Kortmansky, M. Motwani, M. Drobnjak, M. Gonen, S. Yi, A. Weyerbacher, C. Cordon-Cardo, R. Lefkowitz, B. Brenner, et al.
A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol
Clin. Cancer Res., May 15, 2005; 11(10): 3836 - 3845.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. Shah, N. Kemeny, A. Hummer, M. Drobnjak, M. Motwani, C. Cordon-Cardo, M. Gonen, and G. K. Schwartz
Drg1 Expression in 131 Colorectal Liver Metastases: Correlation with Clinical Variables and Patient Outcomes
Clin. Cancer Res., May 1, 2005; 11(9): 3296 - 3302.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
H. G. Moore, J. Shia, D. S. Klimstra, L. Ruo, M. Mazumdar, G. K. Schwartz, B. D. Minsky, L. Saltz, and J. G. Guillem
Expression of p27 in Residual Rectal Cancer after Preoperative Chemoradiation Predicts Long-term Outcome
Ann. Surg. Oncol., November 1, 2004; 11(11): 955 - 961.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. N. Tse and G. K. Schwartz
Potentiation of Cytotoxicity of Topoisomerase I Poison by Concurrent and Sequential Treatment with the Checkpoint Inhibitor UCN-01 Involves Disparate Mechanisms Resulting in Either p53-Independent Clonogenic Suppression or p53-Dependent Mitotic Catastrophe
Cancer Res., September 15, 2004; 64(18): 6635 - 6644.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. N. Demidenko and M. V. Blagosklonny
Flavopiridol Induces p53 via Initial Inhibition of Mdm2 and p21 and, Independently of p53, Sensitizes Apoptosis-Reluctant Cells to Tumor Necrosis Factor
Cancer Res., May 15, 2004; 64(10): 3653 - 3660.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
R. I. Fisher, T. P. Miller, and O. A. O'Connor
Diffuse Aggressive Lymphoma
Hematology, January 1, 2004; 2004(1): 221 - 236.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Jung, M. Motwani, J. Kortmansky, F. M. Sirotnak, Y. She, M. Gonen, A. Haimovitz-Friedman, and G. K. Schwartz
The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates {gamma}-Irradiation-Induced Apoptosis in Colon and Gastric Cancer Cells
Clin. Cancer Res., December 1, 2003; 9(16): 6052 - 6061.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Jiang, C. B. Matranga, D. Cai, V. M. Latham Jr., X. Zhang, A. M. Lowell, F. Martelli, and G. I. Shapiro
Flavopiridol-Induced Apoptosis during S Phase Requires E2F-1 and Inhibition of Cyclin A-Dependent Kinase Activity
Cancer Res., November 1, 2003; 63(21): 7410 - 7422.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Aklilu, H. L. Kindler, R. C. Donehower, S. Mani, and E. E. Vokes
Phase II study of flavopiridol in patients with advanced colorectal cancer
Ann. Onc., August 1, 2003; 14(8): 1270 - 1273.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. A. Shabbits, Y. Hu, and L. D. Mayer
Tumor Chemosensitization Strategies Based on Apoptosis Manipulations
Mol. Cancer Ther., August 1, 2003; 2(8): 805 - 813.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Motwani, C. Rizzo, F. Sirotnak, Y. She, and G. K. Schwartz
Flavopiridol Enhances the Effect of Docetaxel in Vitro and in Vivo in Human Gastric Cancer Cells
Mol. Cancer Ther., June 1, 2003; 2(6): 549 - 555.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. T. Kouroukis, A. Belch, M. Crump, E. Eisenhauer, R. D. Gascoyne, R. Meyer, R. Lohmann, P. Lopez, J. Powers, R. Turner, et al.
Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group
J. Clin. Oncol., May 1, 2003; 21(9): 1740 - 1745.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Wittmann, P. Bali, S. Donapaty, R. Nimmanapalli, F. Guo, H. Yamaguchi, M. Huang, R. Jove, H. G. Wang, and K. Bhalla
Flavopiridol Down-Regulates Antiapoptotic Proteins and Sensitizes Human Breast Cancer Cells to Epothilone B-induced Apoptosis
Cancer Res., January 1, 2003; 63(1): 93 - 99.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Motwani, F. M. Sirotnak, Y. She, T. Commes, and G. K. Schwartz
Drg1, a Novel Target for Modulating Sensitivity to CPT-11 in Colon Cancer Cells
Cancer Res., July 15, 2002; 62(14): 3950 - 3955.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. K. Schwartz, E. O'Reilly, D. Ilson, L. Saltz, S. Sharma, W. Tong, P. Maslak, M. Stoltz, L. Eden, P. Perkins, et al.
Phase I Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination With Paclitaxel in Patients With Advanced Solid Tumors
J. Clin. Oncol., April 15, 2002; 20(8): 2157 - 2170.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. B. Matranga and G. I. Shapiro
Selective Sensitization of Transformed Cells to Flavopiridol-induced Apoptosis following Recruitment to S-Phase
Cancer Res., March 1, 2002; 62(6): 1707 - 1717.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2001 by the American Association for Cancer Research.